HealthDay News — Liraglutide treatment for weight management is not associated with increased risk of cardiovascular events, according to a study published in Diabetes, Obesity and Metabolism.

Melanie J. Davies, MD, from the University Hospitals of Leicester NHS Trust in the United Kingdom, and colleagues conducted post hoc analysis using data from 5908 participants in 5 randomized, double-blind, placebo-controlled clinical trials of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management, in order to assess cardiovascular risk.

The researchers found that with liraglutide (3.0 mg), 8 participants had positively adjudicated cardiovascular events (1.54 events/1,000 person-years), compared to 10 participants in the comparators group (3.65 events/1000 person-years).

Compared to the non-liraglutide group, the hazard ratio for 3.0 mg liraglutide treatment was 0.42 (95% confidence interval, 0.17 to 1.08).

“In this analysis, liraglutide 3.0 mg treatment was not associated with excess cardiovascular risk,” the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which manufactures liraglutide and sponsored the trials.

Related Articles


Davies MJ, Aronne LJ, Caterson ID, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials [published online September 26, 2017]. Diabetes Obes Metab. doi: 10.1111/dom.13125